MassMutual Private Wealth & Trust FSB Sells 3,094 Shares of Johnson & Johnson $JNJ

MassMutual Private Wealth & Trust FSB reduced its stake in Johnson & Johnson (NYSE:JNJ) by 1.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 201,994 shares of the company’s stock after selling 3,094 shares during the quarter. Johnson & Johnson comprises 1.0% of MassMutual Private Wealth & Trust FSB’s investment portfolio, making the stock its 25th largest position. MassMutual Private Wealth & Trust FSB’s holdings in Johnson & Johnson were worth $37,454,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in JNJ. O Brien Wealth Partners LLC raised its stake in shares of Johnson & Johnson by 7.7% in the 3rd quarter. O Brien Wealth Partners LLC now owns 2,691 shares of the company’s stock valued at $499,000 after purchasing an additional 193 shares during the period. Galvin Gaustad & Stein LLC grew its holdings in shares of Johnson & Johnson by 3.4% during the third quarter. Galvin Gaustad & Stein LLC now owns 16,297 shares of the company’s stock worth $3,022,000 after buying an additional 541 shares in the last quarter. Tilson Financial Group Inc. lifted its stake in Johnson & Johnson by 8.9% in the 3rd quarter. Tilson Financial Group Inc. now owns 1,688 shares of the company’s stock valued at $313,000 after acquiring an additional 138 shares in the last quarter. Mccarter Private Wealth Services LLC boosted its position in Johnson & Johnson by 17.0% during the 3rd quarter. Mccarter Private Wealth Services LLC now owns 4,677 shares of the company’s stock worth $867,000 after acquiring an additional 680 shares during the last quarter. Finally, Tribridge Partners Financial LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $333,000. Institutional investors own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Barclays raised its JNJ price target on strength in key drugs, signaling analyst confidence in the company’s mid-term revenue drivers. Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs
• Positive Sentiment: Deal with the Trump administration gives JNJ tariff exemptions and accelerates a reported ~$55 billion plan to expand U.S. manufacturing — this reduces tariff risk, improves supply-chain resilience and could support margins over time. J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
• Positive Sentiment: Clinical and product-development catalysts: mid-stage success for nipocalimab in SLE and J&J MedTech’s Ottava surgical robot submission to the FDA could drive future revenue and sentiment if approvals/commercialization progress. J&J succeeds in mid-stage trial for SLE therapy Johnson & Johnson MedTech submits Ottava surgical robot to FDA
• Neutral Sentiment: Sector tailwind: healthcare stocks have been rallying and JNJ sits in many health-care ETFs, which can provide passive-buying support independent of company-specific news. This ETF Is Proof That the Healthcare Rebound Is Real
• Neutral Sentiment: Partnerships and collaborations (e.g., Lexeo on cardiac gene therapy) expand J&J’s pipeline exposure but are longer-term and incremental to near-term earnings. Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson
• Negative Sentiment: JNJ agreed to cut U.S. drug prices as part of the government deal — that creates near- and medium-term revenue/price pressure for affected medicines and is a headline risk for investors focused on margins. Johnson & Johnson reaches deal with US government to lower drug prices
• Negative Sentiment: Zacks trimmed several near-term EPS estimates (Q1–Q4 and FY2027) marginally — this reflects some analyst caution after the pricing agreement and contributes to downward pressure on the stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $193.00 to $208.00 and gave the stock a “market perform” rating in a research report on Friday. BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Argus set a $210.00 target price on Johnson & Johnson in a report on Wednesday, October 15th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $213.33.

Johnson & Johnson Price Performance

Shares of JNJ opened at $204.47 on Friday. The company’s 50-day moving average is $202.87 and its 200-day moving average is $184.52. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm has a market capitalization of $492.62 billion, a PE ratio of 19.74, a PEG ratio of 2.11 and a beta of 0.34. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $215.18.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.